Academic News RESCUE BT trial results published in JAMA journal!

A multicenter, randomized, placebo-controlled, double-blind clinical trial of intravenous tirofiban before endovascular therapy for acute large vessel occlusion (RESCUE BT) was conducted by the Department of Neurology, Second Affiliated Hospital of Army Medical University (Chongqing Xinqiao Hospital) The team of Professor Yang Qingwu and Professor Zi Wenjie of the Medical Center cooperated with 54 hospitals across the country.

Stroke is the first fatal and disabling disease in China.

Tirofiban is a non-peptide platelet glycoprotein IIb/IIIa receptor antagonist

The RESCUE BT trial focused on a major clinical issue in the current field of stroke care—whether tirofiban can reduce the severity of disability in patients with acute anterior circulation large vessel occlusive stroke receiving endovascular therapy

Results of an intention-to-treat analysis of the study showed that intravenous tirofiban before endovascular therapy did not significantly improve clinical outcomes in patients with large vessel occlusive stroke, but subgroup analysis suggested that large atherosclerotic stroke may benefit from intravenous tirofiban off-campus treatment

The results of the trial show that not all patients with large vessel occlusive stroke can receive intravenous tirofiban therapy, and patients with large artery atherosclerotic stroke can be considered for intravenous tirofiban combined with endovascular therapy if there are no obvious contraindications

Source: "Western Stroke Intervention" official account